Chinook Therapeutics to Host Conference Call and Webcast
SEATTLE, May 25, 2021 (GLOBE NEWSWIRE) – Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision drugs for kidney disease, today announced that the company to host a live conference call and webcast on Tuesday, June 8, 2021 at 1:00 p.m. PDT to discuss interim data from Part 3 of Chinook’s ongoing Phase 1b study of BION-1301 in patients with IgA nephropathy which will be presented at 58e ERA-EDTA Congress. Members of the Chinook management team will be joined by Dr Jonathan Barratt, Mayer Professor of Renal Medicine at the University of Leicester.
Details of abstract BION-1301 accepted as oral presentation at 58e The ERA-EDTA congress is as follows:
|Presentation ID FC040:||Interim results of phase 1 and 2 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of BION-1301 in patients with IgA nephropathy|
|Author:||Jonathan Barratt, Ph.D., FRCP, University of Leicester & Leicester General Hospital, Leicester, United Kingdom|
|Session:||Treatment and outcome of glomerulonephritis, Tuesday June 8, 2021 at 8:30 am – 10:00 am CEST|
For more information, please visit the ERA-EDTA website at https://www.era-edta.org/en/virtualcongress2021/.
Conference call and details
To access the call, please dial (844) 309-0604 (national) or (574) 990-9932 (international) and provide conference ID 2591818 to the operator.
To access the live webcast and subsequent archived recording of this and other presentations from the company, please visit the Investors section of the Chinook website. The archived webcast will remain available for replay on the Chinook website for 90 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision drugs for kidney disease. Chinook’s product candidates are being investigated in rare and severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s flagship program is Atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and serious chronic kidney diseases. Chinook builds its pipeline by leveraging knowledge of kidney single-cell RNA sequencing, human-derived organoids, and novel translational models, to discover and develop therapies with differentiating mechanisms of action against key pathways kidney disease. To learn more, visit www.chinooktx.com.